161 related articles for article (PubMed ID: 26031588)
1. Tacrolimus reduction with everolimus addition for calcineurin inhibitor-induced arteriolopathy in kidney allografts.
Miura M; Higashiyama H; Fukasawa Y; Itoh Y; Tamaki T
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():58-60. PubMed ID: 26031588
[TBL] [Abstract][Full Text] [Related]
2. Arteriosclerosis in zero-time biopsy is a risk factor for tacrolimus-induced chronic nephrotoxicity.
Yagisawa T; Omoto K; Shimizu T; Ishida H; Tanabe K
Nephrology (Carlton); 2015 Jul; 20 Suppl 2():51-7. PubMed ID: 26031587
[TBL] [Abstract][Full Text] [Related]
3. Three-year Outcomes in De Novo Liver Transplant Patients Receiving Everolimus With Reduced Tacrolimus: Follow-Up Results From a Randomized, Multicenter Study.
Fischer L; Saliba F; Kaiser GM; De Carlis L; Metselaar HJ; De Simone P; Duvoux C; Nevens F; Fung JJ; Dong G; Rauer B; Junge G;
Transplantation; 2015 Jul; 99(7):1455-62. PubMed ID: 26151607
[TBL] [Abstract][Full Text] [Related]
4. Effect of low-dose tacrolimus with mycophenolate mofetil on renal function following liver transplantation.
Hao JC; Wang WT; Yan LN; Li B; Wen TF; Yang JY; Xu MQ; Zhao JC; Wei YG
World J Gastroenterol; 2014 Aug; 20(32):11356-62. PubMed ID: 25170222
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Elective Conversion From Sotrastaurin (STN) to Tacrolimus (TAC) or Mycophenolate (MPS) in Stable Kidney Transplant Recipients.
Hannun P; Felipe C; Ferreira A; Sandes-Freitas T; Cristelli M; Aguiar W; Franco M; Campos E; Gerbase de Lima M; Tedesco-Silva H; Medina-Pestana J
Ther Drug Monit; 2016 Jun; 38(3):293-9. PubMed ID: 26919549
[TBL] [Abstract][Full Text] [Related]
6. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A
Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007
[TBL] [Abstract][Full Text] [Related]
7. Evaluating the efficacy, safety and evolution of renal function with early initiation of everolimus-facilitated tacrolimus reduction in de novo liver transplant recipients: Study protocol for a randomized controlled trial.
Nashan B; Schemmer P; Braun F; Dworak M; Wimmer P; Schlitt H
Trials; 2015 Mar; 16():118. PubMed ID: 25873064
[TBL] [Abstract][Full Text] [Related]
8. Subclinical Lesions and Donor-Specific Antibodies in Kidney Transplant Recipients Receiving Tacrolimus-Based Immunosuppressive Regimen Followed by Early Conversion to Sirolimus.
de Sandes-Freitas TV; Felipe CR; Campos ÉF; de Lima MG; Soares MF; de Franco MF; Aguiar WF; Tedesco-Silva H; Medina-Pestana JO
Transplantation; 2015 Nov; 99(11):2372-81. PubMed ID: 25929604
[TBL] [Abstract][Full Text] [Related]
9. Calcineurin Inhibitor Nephrotoxicity Through the Lens of Longitudinal Histology: Comparison of Cyclosporine and Tacrolimus Eras.
Nankivell BJ; PʼNg CH; OʼConnell PJ; Chapman JR
Transplantation; 2016 Aug; 100(8):1723-31. PubMed ID: 27306529
[TBL] [Abstract][Full Text] [Related]
10. Early withdrawal of calcineurin inhibitor from a sirolimus-based immunosuppression stabilizes fibrosis and the transforming growth factor-β signalling pathway in kidney transplant.
Rivelli RF; Gonçalves RT; Leite M; Santos MA; Delgado AG; Cardoso LR; Takiya CM
Nephrology (Carlton); 2015 Mar; 20(3):168-76. PubMed ID: 25404086
[TBL] [Abstract][Full Text] [Related]
11. Controlled randomized study comparing the cardiovascular profile of everolimus with tacrolimus in renal transplantation.
Cruzado JM; Pascual J; Sánchez-Fructuoso A; Serón D; Díaz JM; Rengel M; Oppenheimer F; Hernández D; Paravisini A; Saval N; Morales JM;
Transpl Int; 2016 Dec; 29(12):1317-1328. PubMed ID: 27648523
[TBL] [Abstract][Full Text] [Related]
12. Tacrolimus and Everolimus de novo versus minimization of standard dosage of Tacrolimus provides a similar renal function at one year after liver transplantation: a case-control matched-pairs analysis.
Mocchegiani F; Montalti R; Nicolini D; Svegliati Baroni G; Benedetti A; Risaliti A; Vivarelli M
Ann Transplant; 2014 Oct; 19():545-50. PubMed ID: 25347718
[TBL] [Abstract][Full Text] [Related]
13. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes.
Shihab F; Christians U; Smith L; Wellen JR; Kaplan B
Transpl Immunol; 2014 Jun; 31(1):22-32. PubMed ID: 24861504
[TBL] [Abstract][Full Text] [Related]
14. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial.
De Simone P; Nevens F; De Carlis L; Metselaar HJ; Beckebaum S; Saliba F; Jonas S; Sudan D; Fung J; Fischer L; Duvoux C; Chavin KD; Koneru B; Huang MA; Chapman WC; Foltys D; Witte S; Jiang H; Hexham JM; Junge G;
Am J Transplant; 2012 Nov; 12(11):3008-20. PubMed ID: 22882750
[TBL] [Abstract][Full Text] [Related]
15. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
Gullestad L; Iversen M; Mortensen SA; Eiskjaer H; Riise GC; Mared L; Bjørtuft O; Ekmehag B; Jansson K; Simonsen S; Gude E; Rundqvist B; Fagertun HE; Solbu D; Bergh CH
Transplantation; 2010 Apr; 89(7):864-72. PubMed ID: 20061999
[TBL] [Abstract][Full Text] [Related]
16. Pilot conversion trial from mycophenolic acid to everolimus in ABO-incompatible kidney-transplant recipients with BK viruria and/or viremia.
Belliere J; Kamar N; Mengelle C; Allal A; Sallusto F; Doumerc N; Game X; Congy-Jolivet N; Esposito L; Debiol B; Rostaing L
Transpl Int; 2016 Mar; 29(3):315-22. PubMed ID: 26575959
[TBL] [Abstract][Full Text] [Related]
17. Induction Immunosuppressive Therapy With Everolimus and Low-Dose Tacrolimus Extended-Release Preserves Good Renal Function at 1 Year After Kidney Transplantation.
Yamanaka K; Kakuta Y; Nakazawa S; Kato T; Abe T; Imamura R; Okumi M; Ichimaru N; Kyo M; Kyakuno M; Takahara S; Nonomura N
Transplant Proc; 2016 Apr; 48(3):781-5. PubMed ID: 27234735
[TBL] [Abstract][Full Text] [Related]
18. High Intrapatient Tacrolimus Variability Is Associated With Worse Outcomes in Renal Transplantation Using a Low-Dose Tacrolimus Immunosuppressive Regime.
Whalen HR; Glen JA; Harkins V; Stevens KK; Jardine AG; Geddes CC; Clancy MJ
Transplantation; 2017 Feb; 101(2):430-436. PubMed ID: 26950724
[TBL] [Abstract][Full Text] [Related]
19. The safety of calcineurin inhibitors for kidney-transplant patients.
Malvezzi P; Rostaing L
Expert Opin Drug Saf; 2015 Oct; 14(10):1531-46. PubMed ID: 26329325
[TBL] [Abstract][Full Text] [Related]
20. Protective effect of mycophenolate mofetil against nephrotoxicity and hepatotoxicity induced by tacrolimus in Wistar rats.
Ferjani H; El Arem A; Bouraoui A; Achour A; Abid S; Bacha H; Boussema-Ayed I
J Physiol Biochem; 2016 Jun; 72(2):133-44. PubMed ID: 26746208
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
